総合診療33巻1号

2023年01月発行

特集 COVID-19パンデミック 振り返りと将来への備え 【COVID-19診療・対策振り返り編—新型コロナウイルスが教えてくれたこと】

—臨床❶感染症専門医—COVID-19流行が浮き彫りにした臨床現場の3つの問題

著者： 黒田浩一¹

所属機関： ¹神戸市立医療センター中央市民病院 感染症科

ページ範囲：P.24 - P.29

　COVID-19（新型コロナウイルス感染症）の流行は、私たち感染症専門医に多くの問題を投げかけた。筆者は、比較的規模の大きな地方都市（兵庫県神戸市、人口約150万人）の第一種感染症指定医療機関で、流行当初からCOVID-19の診療に直接関わってきた。その間、「診断」「治療」「感染対策」「病院レベルでの医療体制の構築」「行政との関係」「感染症専門医の存在意義」などの問題に何度も直面し、そのつど試行錯誤を重ね、なんとか対応してきた。本稿では、筆者が現場で経験したこれらのうち、診断・治療・感染対策の3つの問題について振り返る。

参考文献

1）厚生労働省：新型コロナウイルス感染症COVID-19 診療の手引き 第8.1版，2022. https://www.mhlw.go.jp/content/000936655.pdf

2）RECOVERY Collaborative Group, et al : Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384（8） : 693-704, 2021. PMID 32678530

3）Doi Y, et al : A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 64（12） : e01897-20, 2020. PMID 32958718

4）Ezer N, et al : Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients : CONTAIN phase II randomised controlled trial. BMJ 375 : e068060, 2021. PMID 34728476

5）Cao B, et al : A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382（19） : 1787-1799, 2020. PMID 32187464

6）Bosaeed M, et al : Favipiravir and hydroxychloroquine combination therapy in patients with moderate to severe COVID-19 （FACCT Trial） ; an open-label, multicenter, randomized, controlled trial. Infect Dis Ther 10（4） : 2291-2307, 2021. PMID 34319552

7）Hassanipour S, et al : The efficacy and safety of Favipiravir in treatment of COVID-19 ; a systematic review and meta-analysis of clinical trials. Sci Rep 11（1） : 11022, 2021. PMID 34040117

8）Shinkai M, et al : Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy ; a randomized, phase III clinical trial. Infect Dis Ther 10（4） : 2489-2509, 2021. PMID 34453234

9）Golan Y, et al : Favipiravir in patients with early mild-to-moderate COVID-19 ; a randomized controlled trial. Clin Infect Dis ciac712, 2022. ［online ahead of print］ PMID 36065065

10）REMAP-CAP Investigators, et al : Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med 384（16） : 1491-1502, 2021. PMID 33631065

11）RECOVERY Collaborative Group : Tocilizumab in patients admitted to hospital with COVID-19 （RECOVERY） ; a randomised, controlled, open-label, platform trial. Lancet 397（10285） : 1637-1645, 2021. PMID 33933206

12）Marconi VC, et al : Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 （COV-BARRIER） ; a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 9（12） : 1407-1418, 2021. PMID 34480861

13）Beigel JH, et al : Remdesivir for the treatment of Covid-19 - final report. N Engl J Med 383（19） : 1813-1826, 2020. PMID 32445440

14）WHO Solidarity Trial Consortium : Remdesivir and three other drugs for hospitalised patients with COVID-19 ; final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 399（10339） : 1941-1953, 2022. PMID 35512728

15）Hammond J, et al : Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 386（15） : 1397-1408, 2022. PMID 35172054

16）Arbel R, et al : Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge. N Engl J Med 387（9） : 790-798, 2022. PMID 36001529

17）Ganatra S, et al : Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with Covid-19. Clin Infect Dis ciac673, 2022. ［online ahead of print］ PMID 35986628

18）Gottlieb RL, et al : Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 386（4） : 305-315, 2022. PMID 34937145

19）Jayk Bernal A, et al : Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 386（6） : 509-520, 2022. PMID 34914868

20）Weinreich DM, et al : REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med 385（23） : e81, 2021. PMID 34587383

21）Gupta A, et al : Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 385（21） : 1941-1950, 2021. PMID 34706189

22）厚生労働省：薬事・食品衛生審議会 令和4年度第5回薬事分科会，令和4年度第13回医薬品第二部会（合同開催）資料（令和4年11月22日），2022. https://www.mhlw.go.jp/stf/newpage_29325.html

23）Salvarani C, et al : Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial. Eur Respir J 60（4） : 2200025, 2022. PMID 35361632

24）Bouadma L, et al : High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure ; The COVIDICUS randomized clinical trial. JAMA Intern Med 182（9） : 906-916, 2022. PMID 35361632

25）Reis G, et al : Effect of early treatment with ivermectin among patients with Covid-19. N Engl J Med 386（18） : 1721-1731, 2022. PMID 35353979

26）Tardif JC, et al : Colchicine for community-treated patients with COVID-19 （COLCORONA） ; a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 9（8） : 924-932, 2021. PMID 34051877

27）NIH : COVID-19 treatment guidelines. Therapeutic Management of Nonhospitalized Adults With COVID-19. ［last updated : Sep 26, 2022］ https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/

28）Agarwal A, et al : A living WHO guideline on drugs for covid-19. BMJ 370 : m3379, 2020. PMID 32887691

29）Bartoletti M, et al : European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019; an update on treatment of patients with mild/moderate disease. Clin Microbiol Infect S1198-743X（22）00429-3, 2022. ［online ahead of print］ PMID 36028088

30）厚生労働省：中和抗体薬「ロナプリーブ」「ゼビュディ」について．第100回新型コロナウイルス感染症対策アドバイザリーボード（令和4年9月21日）参考資料1, 2022. https://www.mhlw.go.jp/content/10900000/000992311.pdf

31）Gold JAW, et al : Dispensing of oral antiviral drugs for treatment of COVID-19 by zip code-level social vulnerability - United States, December 23, 2021-May 21, 2022. MMWR Morb Mortal Wkly Rep 71（25） : 825-829, 2022. PMID 35737571

32）Butler C, et al : Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes （PANORAMIC） ; preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial. 2022. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4237902

33）He X, et al : Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 26（5） : 672-675, 2020. PMID 32296168

34）Ferretti L, et al : Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science 368（6491） : eabb6936, 2020. PMID 32234805

35）日本環境感染学会：医療機関における新型コロナウイルス感染症への対応ガイド 第3版，2020. http://www.kankyokansen.org/uploads/uploads/files/jsipc/COVID-19_taioguide3.pdf

36）Belan M, et al : SARS-CoV-2 exposures of healthcare workers from primary care, long-term care facilities and hospitals ; a nationwide matched case-control study. Clin Microbiol Infect 28（11） : 1471-1476, 2022. PMID 35777605

37）Klompas M, et al : Preventing SARS-CoV-2 transmission in health care settings in the context of the Omicron variant. JAMA 327（7） : 619-620, 2022. PMID 35072715

38）Dörr T, et al : Risk of SARS-CoV-2 acquisition in health care workers according to cumulative patient exposure and preferred mask type. JAMA Netw Open 5（8） : e2226816, 2022. PMID 35969403

39）Centers for Disease Control and Prevention : COVID-19 Infection Control Guidance ［last updated: Sep 23, 2022］． https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html